ClinicalTrials.gg
RecruitingNCT05740839HYPEUpdated Nov 6, 2026

High-Intensity Interval Exercise in Young Adult Survivors of Pediatric Brain Tumors: A Pilot Feasibility Study

An interventional study of HIIT Exercise Program and Control Group in Pediatric Brain Tumor, sponsored by Dana-Farber Cancer Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Dana-Farber Cancer Institute · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.
Updated Nov 6, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Brain Neoplasms by Dana-Farber Cancer Institute — 4 open to participants now, 7 under way, none of them phase 3. Brain Neoplasms · Dana-Farber Cancer Institute.

Planned enrollment
10th of 12
30 · median 43
Started
2023
the only one that year
No phase
4 of 15
4 open now
Registered
13th of 15
by date

Among the 15 studies in Brain Neoplasms by Dana-Farber Cancer Institute, this one is the 10th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2023, is one of 4 with no phase, and was the 13th registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

4 of the 15 studies in Brain Neoplasms by Dana-Farber Cancer Institute are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Brain Neoplasms by Dana-Farber Cancer Institute, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether a 16-week virtual, home-based, high-intensity interval training (HIIT) exercise program will improve physical, cognitive, and emotional health among young adult survivors of pediatric brain tumors.

The names of the study interventions involved in this study are/is:

  • High-Intensity Interval Training (HIIT)
Read the detailed description

This is a Pilot/Feasibility, randomized control, research study that will compare an exercise group to a control group on physical, social, and overall quality of life needs of pediatric brain tumor survivors who are now young adults.

Participants will be randomized (selected at random) for two groups: HIIT program group will complete a 16-week intervention period followed by a 16-week period with no intervention and the waitlisted control group will complete a 16-week period and will perform their usual, daily activities followed by an optional 16-week period in which they can complete the HIIT program.

Research procedures include screening for eligibility, study treatment including in-clinic evaluations of fitness and strength, blood collection, at-home zoom exercise sessions, self-administered activity logs, and survey questionnaires.

Participation in this research study is expected to last about 8 months.

It is expected that about 30 people will take part in this research study.

The Stahl Family Charitable Foundation, Pedal 4 Pediatrics, and the Childhood Brain Tumor Foundation are supporting this research study by providing funding for the study.

03

Conditions studied

  • Pediatric Brain Tumor

Browse trials for

Keywords

  • Pediatric Brain Tumor
  • Exercise Program
  • HIIT Program
  • Pediatric Brain Tumor Survivors
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written prior to any study-related procedures.
  • At time of study are a young adult, aged 18-45 years.
  • diagnosed brain tumor during childhood, or currently diagnosed with an IDH-mutant glioma (diagnosed > 18 years).
  • Are at least 2 years post tumor-directed therapy for pediatric brain tumor survivors, or at least 1 year since their most recent surgery, radiation or chemotherapy treatment for IDH-mutant glioma patients (or are deemed able to participate in the study based on the assessment of their treating physician). IDH-mutant glioma patients can participate while on maintenance therapy with an IDH inhibitor.
  • The effects of exercise on the developing fetus are unknown. For this reason, people of must verify pregnancy status by providing first day of their last menstrual cycle and agree to use adequate (hormonal or barrier method of birth control or abstinence) prior to study entry. Should a person become pregnant or suspect that they are pregnant while participating on the trial, they should inform their treating physician immediately.
  • Medically cleared to participate in exercise by their referring physician or a certified clinical exercise physiologist.
  • If participants have a diagnosis of tumor-related epilepsy, they must have good seizure control, with no generalized seizures in the 6 months preceding enrollment.
  • Are without any other medical conditions that could exacerbate with exercise, such as bone disease (excluding bone ) at imminent risk of fracture or uncontrolled cardiopulmonary or metabolic diseases.
  • Speak English and/or Spanish.
  • Currently participate in less than or equal to 60 minutes of moderate or vigorous structured exercise/week.
  • Does not smoke cigarettes or e-cigarettes (no smoking during the previous 12 months). Those who infrequently smoke in social settings will be included. Those who vape will also be included.
  • Willing to travel to DFCI for necessary data collection.
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of primary spinal cord tumor.
  • Pre-existing medical conditions such as uncontrolled tumor-related epilepsy, cardiopulmonary disease, or metabolic diseases that could exacerbate with exercise.
  • Patients with evidence of progressive CNS or systemic cancer in the last 3 months.
  • People who are pregnant, or plan to become pregnant during study duration will be excluded due to the unknown nature of exercise on developing fetuses.
  • Actively on a weight loss diet.
  • Participate in more than 60 minutes of moderate or vigorous structured exercise/week.
  • Currently and regularly smokes.
  • Unable to travel to DFCI for necessary data collection.
  • May not be able to comply with the safety monitoring requirements of the study in the opinion of the investigator.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    HIIT Exercise Program Group

    Participants will be randomly assigned to the HIIT exercise group and receive: * 3x weekly for 16 week home-based virtually supervised High-Intensity Interval Training. * 16-week self-directed exercise follow up period. * 3 On-site visits at Week 1, 18 and 34 for assement testing and completion of questionnaires

    Behavioral: HIIT Exercise Program

  • Active comparator
    Control Group

    Participants will be randomly assigned to the HIIT waitlist control group and receive: * Daily usual activities * 2 On-site visits at Week 1, and 18 for assement testing and completion of questionnaires * Option to complete 16 week, 3x weekly HIIT exercise program after initial 16 week period.

    Behavioral: Control Group

Interventions

  • BehavioralHIIT Exercise Program

    Exercise program with stationary bike via the Zoom platform.

    Also known as: High-Intensity Interval Training

  • BehavioralControl Group

    Usual Activities

06

What researchers measure

Primary outcomes

  1. Attendance of Exercise Sessions

    Defined as participant attendance of \>= 70% of the 48 HIIT exercise sessions.

    Time frame: From first exercise session to final exercise session, up to 16 weeks

  2. Completion in Minutes of Exercise Sessions

    Defined as participant completion of \>= 70% of the 90 minutes of exercise per week

    Time frame: From first exercise session to final exercise session, up to 16 weeks

  3. HIIT Compliance

    Defined as obtaining +-5W of target power output for \>= 40 seconds of high intensity minute

    Time frame: From first exercise session to final exercise session, up to 16 weeks

  4. Barriers to Exercise Adherence

    Assessed through the 17-item Barriers to Recruitment Participation Questionnaire (BRPQ), 1-5 scale with 1 denoted as strongly agree and 5 as strongly disagree.

    Time frame: From first exercise session to final exercise session, up to 16 weeks

  5. Participant Burden

    Assessed through the Perceived Research Burden Assessment (PRBA), 1-5 scale with 1 denoted as strongly disagree and 5 as strongly agree.

    Time frame: From first exercise session to final exercise session, up to 16 weeks

Secondary outcomes

  1. Cognition

    An assortment of tests will be executed through the NIH toolbox to measure overall cognition.

    Time frame: : From baseline to post-intervention, up to 43 weeks

  2. Cardiorespiratory Fitness

    Assessed through the use of a VO2 max (or submaximal if equipment is unavailable) cycle exercise stress test (Parvo Medics TrueOne 2400; Sandy, UT, USA).

    Time frame: From baseline to post-intervention, up to 43 weeks

  3. Muscular Strength

    10-repetition maximum will be used to assess muscular strength.

    Time frame: From baseline to post-intervention, up to 43 weeks

  4. Body Composition

    Bioelectrical Impedance Analysis (BIA), and blood pressure as measured twice on both arms with a seated position with a minimum of 1-minute interval and the higher pressure will be recorded when there are differences. BIA: Assessed via bioelectrical impedance using a validated device (Tanita 780, Arlington Heights, IL). Participants will be asked to remove their shoes and socks after which height will be taken using a stadiometer they will then proceed to move to the BIA and stand still on the device while holding the handles with their hands at their sides. The device will estimate body fat using an algorithm based on their age, sex, height, and body weight.

    Time frame: From baseline to post-intervention, up to 43 weeks

  5. Fatigue

    BFI: A questionnaire of scale ratings 0 - 10 that focuses on cancer-related fatigue and tiredness.

    Time frame: From baseline to post-intervention, up to 43 weeks

  6. Psychosocial Health

    Assessed through the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire, which is comprised of 27 items with scale ratings validated to measure physical, emotional, social, and functional well-being of cancer patients and survivors

    Time frame: From baseline to post-intervention, up to 43 weeks

  7. Quality of Sleep

    Assessed through the Pittsburg Sleep Quality Index (PSQI), which is used to measure 7 components of the quality and patterns of sleep in participants.

    Time frame: From baseline to post-intervention, up to 43 weeks

  8. Dietary Assessment, ASA-24

    Participants will be provided with a login to enter dietary data measured by an automated, online self-administered 24-hour assessment tool.

    Time frame: Up to 3 days

  9. ActiGraph - Physical Activity Monitoring

    Participants will be provided with an accelerometer (ActiGraph, Pensacola, FL) to wear for seven days at baseline and post-intervention testing visits and will be instructed to wear the water-resistant accelerometer at all times except for when swimming or bathing. The device will record activity data and will be electronically transferred to a computer via USB cable at time of completion.

    Time frame: From baseline to post-intervention, up to 27 weeks

  10. Exercise Tolerance

    Will be recorded using the Exercise-Induced Feeling Inventory (EIF). Based on a 0-4 scale, it assesses the participant's feeling state change(s) post-exercise and is also used for the assessment of self-motivation to adhere to an exercise regimen. Participants will be asked to complete the inventory before and after each exercise session.

    Time frame: From baseline to week 16, up to 32 weeks

  11. Pain Index

    BPI: A 9 item questionnaire to evaluate the severity of pain and the impact of pain on the participant's daily functioning.

    Time frame: From baseline to post-intervention, up to 43 weeks

  12. Hip and Waist Circumference

    Hip and waist circumference will be assessed and recorded in cm.

    Time frame: From baseline to post-intervention, up to 43 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Sep 2027, 45 months after the start.

Of 310 non-industry interventional studies with no phase under Brain Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 45 months is below that.

Counting every sponsor, half of 321 studies reached it within 64 months; a quarter within 35 and three quarters within 125.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Sep 2026 → Sep 2027 and completion Sep 2027 → Sep 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2023
First posted
Feb 23, 2023
StartActual
Dec 4, 2023
Primary completionEst.
Sep 24, 2027was Sep 2026
CompletionEst.
Sep 24, 2028was Sep 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 24, 2026→Sep 24, 2027
Nov 6, 2026
Study completion
Sep 24, 2027→Sep 24, 2028
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Primary completion Sep 24, 2026→Sep 24, 2027
    Study completion Sep 24, 2027→Sep 24, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05740839
Collaborators
Stahl Family Charitable Foundation, The Childhood Brain Tumor Foundation, Pedals For Pediatrics
Responsible party
Christina Dieli-Conwright, PhD (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Feb 23, 2023
Start date
Dec 4, 2023
Primary completion
Sep 24, 2027 (estimated)
Completion
Sep 24, 2028 (estimated)
Last update
Nov 6, 2026

Study contacts

Christina Dieli-Conwright, PhD, MPH
Contact
ChristinaM_Dieli-Conwright@dfci.harvard.edu
617-582-8321
Christina Dieli-Conwright, PhD, MPH
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion